婴儿白 - 撒尔科格利干 (SGCE) 肌细胞结核 - 肌:诊断陷和对药物治疗的反应不佳
Rita Pissarra1,2, Leonor Dias3,4, Raquel Sousa5,2
1Pediatrics, Unidade Local de Saúde São João, Porto, PRT.
持续的婴儿肌细胞瘤可以信号遗传运动障碍. 这一案例突出显示了因Epsilon-Sarcoglycan (SGCE) 基因变异而诊断的肌结核- dystonia综合征 (MDS),强调了基因检测和长期护理.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 儿科 儿科 儿科
背景情况:
- 婴儿肌细胞瘤通常是良性的,但持久的形式可能表明严重的神经疾病.
- 肌结核-静脉缩综合征 (MDS) 是一种罕见的遗传运动障碍,与Epsilon-Sarcoglycan (SGCE) 基因有关.
- 早期发病的MDS由于症状与其他疾病重叠而带来诊断挑战.
研究的目的:
- 报告儿科患者患有早期发病的肌肉质结核 - dystonia 综合征,呈现为孤立的肌肉质结核.
- 突出SGCE相关的MDS的诊断困难和管理.
- 强调基因检测和长期随访的重要性,以获得有利的结果.
主要方法:
- 一个六岁女孩的病例报告,患有肌和 dystonia.
- 综合的神经学,神经成像,脑电图和代谢调查.
- 基因检测用于识别SGCE基因中的致病变体.
主要成果:
- 该患者被诊断患有肌结核-静脉缩综合征,原因是异性致病性SGCE变种.
- 标准的抗和抗肌药物显示出有限的疗效.
- 运动和认知发育保持在平均范围内,以后出现行为问题.
结论:
- 早期出现的SGCE肌结肠可以呈现为孤立的肌结肠,这带来了诊断挑战.
- 基因检测对于MDS的准确诊断至关重要.
- 长期的多学科随访对于管理相关的行为症状和确保有利的功能结果至关重要.
更多相关视频
10:05Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia
Published on: January 27, 2018
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
相关概念视频
Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Appendicitis-II: Diagnostic Studies and Management
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Drug Abuse and Addiction: Pharmacological Phenomena
Cardiopulmonary Resuscitation IV: Pharmacological Management
